CN104470899B - 作为hif羟化酶抑制剂的4‑羟基‑异喹啉化合物 - Google Patents
作为hif羟化酶抑制剂的4‑羟基‑异喹啉化合物 Download PDFInfo
- Publication number
- CN104470899B CN104470899B CN201380023358.XA CN201380023358A CN104470899B CN 104470899 B CN104470899 B CN 104470899B CN 201380023358 A CN201380023358 A CN 201380023358A CN 104470899 B CN104470899 B CN 104470899B
- Authority
- CN
- China
- Prior art keywords
- hydroxy
- amino
- isoquinoline
- carbonyl
- cyano
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 *C(c(nc(c1cc(*)c(*)cc11)O)c1O)=O Chemical compound *C(c(nc(c1cc(*)c(*)cc11)O)c1O)=O 0.000 description 9
- LIPLTYRTHVKYLT-UHFFFAOYSA-N CC(C)CC(CC(O)=O)CNC(c1nc(C#N)c(cc(cc2)Oc3ccccc3)c2c1O)=O Chemical compound CC(C)CC(CC(O)=O)CNC(c1nc(C#N)c(cc(cc2)Oc3ccccc3)c2c1O)=O LIPLTYRTHVKYLT-UHFFFAOYSA-N 0.000 description 1
- PDDZFEWPTAIYGL-UHFFFAOYSA-N CCCC(CCC)(CNC(c1nc(C#N)c(cc(cc2)Oc3ccccc3)c2c1O)=O)C(O)=O Chemical compound CCCC(CCC)(CNC(c1nc(C#N)c(cc(cc2)Oc3ccccc3)c2c1O)=O)C(O)=O PDDZFEWPTAIYGL-UHFFFAOYSA-N 0.000 description 1
- OUBAPWWJWLDPAF-UHFFFAOYSA-N CCCC(CNC(c1nc(C#N)c(cc(cc2)Oc3ccccc3)c2c1O)=O)C(O)=O Chemical compound CCCC(CNC(c1nc(C#N)c(cc(cc2)Oc3ccccc3)c2c1O)=O)C(O)=O OUBAPWWJWLDPAF-UHFFFAOYSA-N 0.000 description 1
- QRKPIEXQMYXMLU-UHFFFAOYSA-N Cc(cccc1C)c1Oc(ccc1c(C#N)nc2C(NCCC(O)=O)=O)cc1c2O Chemical compound Cc(cccc1C)c1Oc(ccc1c(C#N)nc2C(NCCC(O)=O)=O)cc1c2O QRKPIEXQMYXMLU-UHFFFAOYSA-N 0.000 description 1
- WXEZHWSFGUKMAJ-UHFFFAOYSA-N N#Cc(c1c2ccc(Oc3ccccc3)c1)nc(C(NC(CC1=CC=CCC1)C(C(O)=O)O)=O)c2O Chemical compound N#Cc(c1c2ccc(Oc3ccccc3)c1)nc(C(NC(CC1=CC=CCC1)C(C(O)=O)O)=O)c2O WXEZHWSFGUKMAJ-UHFFFAOYSA-N 0.000 description 1
- LVXKRGZCCFQOFU-UHFFFAOYSA-N N#Cc(c1c2ccc(Oc3ccccc3)c1)nc(C(NCC1(CC1)C(O)O)=O)c2O Chemical compound N#Cc(c1c2ccc(Oc3ccccc3)c1)nc(C(NCC1(CC1)C(O)O)=O)c2O LVXKRGZCCFQOFU-UHFFFAOYSA-N 0.000 description 1
- DGJDZGFFYSIJTN-NRFANRHFSA-N N#Cc(c1cc(Oc2ccccc2)ccc11)nc(C(N[C@@H](CC(O)=O)c2ccccc2)=O)c1O Chemical compound N#Cc(c1cc(Oc2ccccc2)ccc11)nc(C(N[C@@H](CC(O)=O)c2ccccc2)=O)c1O DGJDZGFFYSIJTN-NRFANRHFSA-N 0.000 description 1
- JSYWJICQZNCWHF-UHFFFAOYSA-N N#Cc(nc1C(NCC2(CCCC2)C(O)=O)=O)c(cc(cc2)Oc3ccccc3)c2c1O Chemical compound N#Cc(nc1C(NCC2(CCCC2)C(O)=O)=O)c(cc(cc2)Oc3ccccc3)c2c1O JSYWJICQZNCWHF-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261609022P | 2012-03-09 | 2012-03-09 | |
| US61/609,022 | 2012-03-09 | ||
| PCT/US2013/029912 WO2013134660A1 (en) | 2012-03-09 | 2013-03-08 | 4 -hydroxy- isoquinoline compounds as hif hydroxylase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104470899A CN104470899A (zh) | 2015-03-25 |
| CN104470899B true CN104470899B (zh) | 2017-12-26 |
Family
ID=48014301
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201380023358.XA Active CN104470899B (zh) | 2012-03-09 | 2013-03-08 | 作为hif羟化酶抑制剂的4‑羟基‑异喹啉化合物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9409892B2 (enExample) |
| EP (1) | EP2834220B1 (enExample) |
| JP (2) | JP6129217B2 (enExample) |
| CN (1) | CN104470899B (enExample) |
| AU (1) | AU2013229922B2 (enExample) |
| CA (1) | CA2866556C (enExample) |
| IL (1) | IL234544A (enExample) |
| NZ (1) | NZ700760A (enExample) |
| SG (1) | SG11201405574UA (enExample) |
| WO (1) | WO2013134660A1 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004108681A1 (en) | 2003-06-06 | 2004-12-16 | Fibrogen, Inc. | Nitrogen-containing heteroaryl compounds and their use in increasing endogenous erythropoietin |
| CN102272117B (zh) | 2008-11-14 | 2015-06-17 | 菲布罗根有限公司 | 作为hif羟化酶抑制剂的苯并噻喃衍生物 |
| CN109369524A (zh) | 2012-07-16 | 2019-02-22 | 菲布罗根有限公司 | 脯氨酰羟化酶抑制剂的晶体形态 |
| US8883823B2 (en) | 2012-07-16 | 2014-11-11 | Fibrogen, Inc. | Crystalline forms of a prolyl hydroxylase inhibitor |
| HUE034409T2 (en) | 2012-07-16 | 2018-02-28 | Fibrogen Inc | Process for the preparation of isoquinoline compounds |
| CN105377242A (zh) | 2013-06-06 | 2016-03-02 | 菲布罗根有限公司 | Hif羟化酶抑制剂的药物制剂 |
| WO2015054579A1 (en) * | 2013-10-11 | 2015-04-16 | Isis Pharmaceuticals, Inc. | Treatment of acute kidney injury with phd1 modulators |
| CN105384687B (zh) | 2014-09-02 | 2018-05-01 | 广东东阳光药业有限公司 | 喹啉酮类化合物及其在药物中应用 |
| CN106146490B (zh) * | 2015-03-27 | 2018-10-23 | 沈阳三生制药有限责任公司 | 被芳氧基或杂芳氧基取代的5-羟基-1,7-萘啶化合物、其制备方法及其制药用途 |
| CN106146395B (zh) | 2015-03-27 | 2019-01-01 | 沈阳三生制药有限责任公司 | 3-羟基吡啶化合物、其制备方法及其制药用途 |
| CN105367435A (zh) * | 2015-12-03 | 2016-03-02 | 张伟 | 一种β-丙氨酸叔丁酯盐酸盐的制备方法 |
| CN107188875B (zh) * | 2016-03-15 | 2020-11-10 | 联化科技股份有限公司 | 一种取代苯酞类化合物的制备方法及其中间体 |
| CN106478503A (zh) * | 2016-09-29 | 2017-03-08 | 上海勋和医药科技有限公司 | Roxadustat中间体的制备方法 |
| KR20190057388A (ko) | 2016-10-10 | 2019-05-28 | 브리스톨-마이어스 스큅 컴퍼니 | Ror 감마 조정제로서의 트리시클릭 술폰 |
| CN107954931B (zh) * | 2016-10-17 | 2021-06-22 | 上海医药集团青岛国风药业股份有限公司 | 一种诺得司他的制备方法 |
| EP3573615B1 (en) | 2017-01-28 | 2024-06-12 | Kingchem Life Science LLC | A process for preparing 5-phenoxy-1(3h)isobenzofuranone |
| TW201920108A (zh) * | 2017-09-25 | 2019-06-01 | 日商武田藥品工業有限公司 | N-(氰基取代之苄基或吡啶基甲基)-3-羥基吡啶醯胺衍生物 |
| CN108084090B (zh) * | 2017-12-20 | 2020-03-17 | 北京六合宁远科技有限公司 | 一种药物中间体含氮杂环的溴代化合物的合成方法 |
| CN112679430B (zh) * | 2019-10-18 | 2023-05-05 | 上海迪赛诺化学制药有限公司 | 一种制备异喹啉酮类化合物的方法 |
| CN112679431B (zh) * | 2019-10-18 | 2023-05-05 | 上海迪赛诺化学制药有限公司 | 一种制备异喹啉酮类化合物的方法 |
| US20230112619A1 (en) * | 2019-10-18 | 2023-04-13 | Shanghai Desano Chemical Pharmaceutical Co., Ltd. | Method for preparing isoquinolinone compounds |
| CN113754569B (zh) * | 2020-06-04 | 2024-07-02 | 四川国为制药有限公司 | 一种中间体化合物及其制备方法和用途 |
| IL312220A (en) * | 2021-10-28 | 2024-06-01 | Insilico Medicine Ip Ltd | Prolyl hydroxylase domain-containing protein (phd) inhibitors and uses thereof |
| JP2025500888A (ja) * | 2021-12-17 | 2025-01-15 | アケビア セラピューティクス インコーポレイテッド | 選択的ｐｈｄ１阻害剤としてのピコリンアミド化合物、組成物、及び使用方法 |
| JP2025500892A (ja) * | 2021-12-17 | 2025-01-15 | アケビア セラピューティクス インコーポレイテッド | 選択的ｐｈｄ１阻害剤化合物、組成物、及び使用方法 |
| AU2023207157A1 (en) * | 2022-01-13 | 2024-07-25 | Fibrogen, Inc. | Treatment for congestive heart failure |
| WO2024138317A1 (zh) * | 2022-12-26 | 2024-07-04 | 中国科学院广州生物医药与健康研究院 | 一种甲状腺激素受体β激动剂化合物及其制备方法和应用 |
| WO2024222893A1 (en) * | 2023-04-28 | 2024-10-31 | Insilico Medicine Ip Limited | Crystalline prolyl hydroxylase domain-containing protein (phd) inhibitor and uses thereof |
| AU2024261389A1 (en) * | 2023-04-28 | 2025-10-30 | Insilico Medicine Ip Limited | Prolyl hydroxylase domain-containing protein (phd) inhibitors, combinations and uses thereof |
| CN121127469A (zh) * | 2023-04-28 | 2025-12-12 | 英矽智能科技知识产权有限公司 | 含脯氨酰羟化酶结构域的蛋白质(phd)抑制剂结晶及其用途 |
| CN117486797A (zh) * | 2023-11-23 | 2024-02-02 | 传健生物医药(厦门)有限公司 | 一种罗沙司他关键中间体及罗沙司他的制备方法 |
| WO2025252553A1 (en) | 2024-06-04 | 2025-12-11 | Syngenta Crop Protection Ag | Pesticidally-active 2,2-dihalocyclopropyl compounds |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1107144A (zh) * | 1993-11-02 | 1995-08-23 | 赫彻斯特股份公司 | 取代的杂环羧酰胺酯，它们的制备及它们作为药物的用途 |
| US7323475B2 (en) * | 2003-06-06 | 2008-01-29 | Fibrogen, Inc. | Nitrogen-containing heteroaryl compounds and methods of use thereof |
| US7928120B2 (en) * | 2006-01-27 | 2011-04-19 | Fibrogen, Inc. | Cyanoisoquinoline compounds and methods of use thereof |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4036964A (en) | 1973-10-11 | 1977-07-19 | Beecham Group Limited | Isocarbostyril-3-carboxylic acid derivatives for the prophylaxis of asthma, hayfever and rhinitis |
| US3989704A (en) | 1973-10-30 | 1976-11-02 | Sandoz, Inc. | 3-Substituted-4-aryl isoquinolines |
| DE2818423A1 (de) | 1978-04-27 | 1979-11-08 | Hoechst Ag | Neue isochinolinderivate und verfahren zu ihrer herstellung |
| DE3233424A1 (de) | 1982-09-09 | 1984-03-15 | Hoechst Ag, 6230 Frankfurt | Isochinolinderivate, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung |
| US4559403A (en) | 1983-05-19 | 1985-12-17 | Hoffmann-La Roche Inc. | Substituted isoquinolines |
| US4584379A (en) | 1985-01-22 | 1986-04-22 | Merrell Dow Pharmaceuticals Inc. | Isoquinoline thromboxane synthetase inhibitors |
| US4822800A (en) | 1986-06-09 | 1989-04-18 | Ortho Pharmaceutical Corporation | Isoquinolinol compounds having cardiotonic and phosphodiesterase fraction III inhibiting properties and/or renal vasodilating properties |
| US4966906A (en) | 1987-11-27 | 1990-10-30 | Hoechst-Roussel Pharmaceuticals Inc. | 1-aryl-3-isoquinolinecarboxamides |
| US4952588A (en) | 1987-11-27 | 1990-08-28 | Hoechst-Roussel Pharmaceuticals Inc. | 1-aryl-3-quinoline-and 1-aryl-3-isoquinoline-carboxamides |
| DK0650961T3 (da) | 1993-11-02 | 1997-09-15 | Hoechst Ag | Substituerede heterocykliske carboxylsyreamider, deres fremstilling og deres anvendelse som lægemidler. |
| CA2138929A1 (en) | 1993-12-30 | 1995-07-01 | Klaus Weidmann | Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals |
| WO1996018616A1 (en) | 1994-12-12 | 1996-06-20 | Merck & Co., Inc. | Substituted 2-aminopyridines as inhibitors of nitric oxide synthase |
| IL135495A (en) | 1995-09-28 | 2002-12-01 | Hoechst Ag | Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid |
| AU5362998A (en) | 1996-11-27 | 1998-06-22 | Du Pont Pharmaceuticals Company | Novel integrin receptor antagonists |
| DE19746287A1 (de) | 1997-10-20 | 1999-04-22 | Hoechst Marion Roussel De Gmbh | Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel |
| FR2779963A1 (fr) | 1998-06-22 | 1999-12-24 | Centre Nat Rech Scient | Utilisation d'un compose possedant une affinite pour le recepteur mitochondrial des benzodiazepines en therapie du cancer |
| IT1302677B1 (it) | 1998-10-15 | 2000-09-29 | Zambon Spa | Derivati benzazinici inibitori della fosfodiesterasi 4 |
| AU4802500A (en) | 1999-04-26 | 2000-11-10 | Neurogen Corporation | 2-aminoquinolinecarboxamides: neurokinin receptor ligands |
| IT1320162B1 (it) | 2000-02-09 | 2003-11-18 | Rotta Research Lab | Derivati della tirosina ad attivita' anti leucotrienica, procedimentoper la loro preparazione e loro uso farmaceutico. |
| FI20002044A0 (fi) | 2000-09-15 | 2000-09-15 | Orion Yhtymae Oyj | Comt-entsyymiä estäviä naftaleenijohdannaisia |
| DE10110750A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| JP2005505507A (ja) | 2001-06-13 | 2005-02-24 | ジーンソフト ファーマシューティカルズ インコーポレイテッド | 抗感染活性を有するイソキノリン化合物 |
| AU2002312371A1 (en) | 2001-06-13 | 2002-12-23 | Roland W. Burli | Aryl-benzimidazole compounds having antiinfective activity |
| US6762318B2 (en) | 2001-12-03 | 2004-07-13 | Novo Nordisk A/S | Glucagon antagonists |
| ES2414706T3 (es) | 2001-12-06 | 2013-07-22 | Fibrogen, Inc. | Métodos para aumentar la eritropoyetina endógena |
| US8124582B2 (en) | 2002-12-06 | 2012-02-28 | Fibrogen, Inc. | Treatment of diabetes |
| US7618940B2 (en) | 2002-12-06 | 2009-11-17 | Fibrogen, Inc. | Fat regulation |
| US8614204B2 (en) | 2003-06-06 | 2013-12-24 | Fibrogen, Inc. | Enhanced erythropoiesis and iron metabolism |
| WO2005007192A2 (en) | 2003-06-06 | 2005-01-27 | Fibrogen, Inc. | Cytoprotection through the use of hif hydroxylase inhibitors |
| CN100418948C (zh) | 2003-07-15 | 2008-09-17 | 麦克公司 | 羟基吡啶cgrp受体抗拮抗剂 |
| WO2005011696A1 (en) | 2003-08-01 | 2005-02-10 | Fibrogen, Inc. | Inhibitors of 2-oxoglutarate dioxygenase as gamma globin inducers |
| US7208601B2 (en) | 2003-08-08 | 2007-04-24 | Mjalli Adnan M M | Aryl and heteroaryl compounds, compositions, and methods of use |
| JP2007501844A (ja) | 2003-08-08 | 2007-02-01 | トランス テック ファーマ，インコーポレイテッド | アリール及びヘテロアリール化合物、組成物並びに使用方法 |
| ATE443775T1 (de) | 2004-05-28 | 2009-10-15 | Fibrogen Inc | Hif-prolylhydroxylase-aktivitätstest |
| ATE513833T1 (de) | 2005-03-02 | 2011-07-15 | Fibrogen Inc | Thienopyridinverbindungen und verfahren zu ihrer verwendung |
| EP1893186A2 (en) | 2005-06-06 | 2008-03-05 | Fibrogen, Inc. | Improved treatment for anemia using a hif-alpha stabilising agent |
| DE602006014843D1 (de) | 2005-06-15 | 2010-07-22 | Fibrogen Inc | Verwendung von hif 1alfa modulatoren zur behandlung von krebs |
| WO2007082899A1 (en) | 2006-01-17 | 2007-07-26 | Vib Vzw | Inhibitors of prolyl-hydroxylase 1 for the treatment of skeletal muscle degeneration |
| BRPI0710527B8 (pt) | 2006-04-04 | 2021-05-25 | Fibrogen Inc | compostos de pirrolo- e tiazolo-piridina e composição farmacêutica que os compreende |
| US7713986B2 (en) | 2006-06-15 | 2010-05-11 | Fibrogen, Inc. | Compounds and methods for treatment of chemotherapy-induced anemia |
| US20070293575A1 (en) | 2006-06-15 | 2007-12-20 | Fibrogen, Inc. | Compounds and methods for treatment of cancer-related anemia |
| BRPI0713350B1 (pt) * | 2006-06-26 | 2022-04-12 | Akebia Therapeutics Inc | Composto, e, composição |
| US8269008B2 (en) | 2007-12-03 | 2012-09-18 | Fibrogen, Inc. | Oxazolopyridine and isoxazolopyridine derivatives for use in the treatment of HIF-mediated conditions |
| WO2009089547A1 (en) | 2008-01-11 | 2009-07-16 | Fibrogen, Inc. | Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity |
| WO2009100250A1 (en) | 2008-02-05 | 2009-08-13 | Fibrogen, Inc. | Chromene derivatives and use thereof as hif hydroxylase activity inhibitors |
| WO2010022240A1 (en) | 2008-08-20 | 2010-02-25 | Fibrogen, Inc. | Pyrrolo [ 1, 2 -b] pyridazine derivatives and their use as hif modulators |
| CN102272117B (zh) | 2008-11-14 | 2015-06-17 | 菲布罗根有限公司 | 作为hif羟化酶抑制剂的苯并噻喃衍生物 |
| BRPI0922366B8 (pt) | 2008-12-03 | 2021-05-25 | Presidio Pharmaceuticals Inc | composto, composição farmacêutica e uso de um composto |
-
2013
- 2013-03-08 SG SG11201405574UA patent/SG11201405574UA/en unknown
- 2013-03-08 WO PCT/US2013/029912 patent/WO2013134660A1/en not_active Ceased
- 2013-03-08 US US14/383,874 patent/US9409892B2/en active Active
- 2013-03-08 NZ NZ700760A patent/NZ700760A/en unknown
- 2013-03-08 AU AU2013229922A patent/AU2013229922B2/en active Active
- 2013-03-08 CA CA2866556A patent/CA2866556C/en active Active
- 2013-03-08 EP EP13712970.6A patent/EP2834220B1/en active Active
- 2013-03-08 CN CN201380023358.XA patent/CN104470899B/zh active Active
- 2013-03-08 JP JP2014561149A patent/JP6129217B2/ja active Active
-
2014
- 2014-09-09 IL IL234544A patent/IL234544A/en active IP Right Grant
-
2017
- 2017-03-13 JP JP2017047346A patent/JP2017101089A/ja active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1107144A (zh) * | 1993-11-02 | 1995-08-23 | 赫彻斯特股份公司 | 取代的杂环羧酰胺酯，它们的制备及它们作为药物的用途 |
| US7323475B2 (en) * | 2003-06-06 | 2008-01-29 | Fibrogen, Inc. | Nitrogen-containing heteroaryl compounds and methods of use thereof |
| CN102718708A (zh) * | 2003-06-06 | 2012-10-10 | 菲布罗根有限公司 | 含氮杂芳基化合物及其在增加内源性促红细胞生成素中的用途 |
| US7928120B2 (en) * | 2006-01-27 | 2011-04-19 | Fibrogen, Inc. | Cyanoisoquinoline compounds and methods of use thereof |
Non-Patent Citations (1)
| Title |
|---|
| Approaches to the design of anti-fibrotic drugs;Trevor J. Franklin，等;《Biochemical Society Transactions》;19911231;第19卷;第812-815页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104470899A (zh) | 2015-03-25 |
| CA2866556A1 (en) | 2013-09-12 |
| US20150038528A1 (en) | 2015-02-05 |
| SG11201405574UA (en) | 2014-10-30 |
| US9409892B2 (en) | 2016-08-09 |
| HK1206743A1 (en) | 2016-01-15 |
| IL234544A (en) | 2017-03-30 |
| AU2013229922A1 (en) | 2014-10-23 |
| JP6129217B2 (ja) | 2017-05-17 |
| EP2834220A1 (en) | 2015-02-11 |
| AU2013229922B2 (en) | 2017-09-28 |
| WO2013134660A1 (en) | 2013-09-12 |
| JP2015509543A (ja) | 2015-03-30 |
| JP2017101089A (ja) | 2017-06-08 |
| NZ700760A (en) | 2016-08-26 |
| CA2866556C (en) | 2020-01-07 |
| EP2834220B1 (en) | 2016-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104470899B (zh) | 作为hif羟化酶抑制剂的4‑羟基‑异喹啉化合物 | |
| CN102264740B (zh) | 一种吡咯[1,2-b]哒嗪衍生物及其作为hif调节剂的用途 | |
| CN103608346B (zh) | 作为缺氧诱导因子(hif)羟化酶抑制剂的萘啶衍生物 | |
| EP1866318B1 (en) | Thienopyridine compounds, and methods of use thereof | |
| CN102272117B (zh) | 作为hif羟化酶抑制剂的苯并噻喃衍生物 | |
| JP4954200B2 (ja) | ヒストン脱アセチル化酵素阻害剤 | |
| CN111094288B (zh) | 具有mgat-2抑制活性的稠合环衍生物 | |
| CN101460497A (zh) | 作为hif调节剂的吡咯并吡啶和噻唑并吡啶化合物 | |
| CN108697715A (zh) | 包含帽依赖性核酸内切酶抑制剂及抗流感药的组合的流感治疗用药物 | |
| CN102702194A (zh) | 抗病毒化合物 | |
| WO2018214980A1 (zh) | 芳酰胺类 Kv2.1 抑制剂及其制备方法、药物组合物和用途 | |
| CN104244939A (zh) | 犬尿氨酸-3-单加氧酶抑制剂、其药物组合物及其使用方法 | |
| CN106068265A (zh) | 用于治疗代谢病症的二氢吡啶酮mgat2抑制剂 | |
| KR20090077975A (ko) | Ｉｋｋ-베타 세린-트레오닌 단백질 키나아제 억제제 | |
| CN105263924B (zh) | Cxcr7受体调节剂 | |
| WO2021063362A1 (zh) | 磺基取代的联芳基类化合物或其盐及其制备方法和用途 | |
| WO2018145653A1 (zh) | 联芳基类化合物及其制备方法和用途 | |
| US8933235B2 (en) | Pyridinedione carboxamide inhibitors of endothelial lipase | |
| HK1206743B (en) | 4-hydroxy-isoquinoline compounds as hif hydroxylase inhibitors | |
| TW201620915A (zh) | ３－氧代－四氫－呋喃並［３，２－ｂ］吡咯－４（５Ｈ）－基）衍生物之二 | |
| WO2022161416A1 (zh) | 一种芳香化合物、其制备方法及应用 | |
| HK40088484A (zh) | 抗病毒素1，3-二氧代茚化合物 | |
| CN101541779A (zh) | IKK-β丝氨酸-苏氨酸蛋白激酶抑制剂 | |
| WO2001083433A1 (en) | Bifunctional inhibitors of malarial proteases and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20200827 Address after: Room 101-601, unit 2, building 7, yard 88, Kechuang 6th Street, Daxing District, Beijing Patentee after: FIBROGEN (CHINA) MEDICINE TECHNOLOGY DEVELOPMENT Co.,Ltd. Address before: California, USA Patentee before: FibroGen, Inc. |